If you have questions about COVID-19 exposure, transmission and/or testing, contact the Northern Arizona Healthcare Coronavirus Hotline at 928-773-2301 or 1-833-708-0894. Get more information.

If you need information on how to obtain a COVID vaccine in Northern Arizona please click here.

As the COVID-19 situation progresses, all Northern Arizona Healthcare facilities have enacted restricted visiting guidelines. Learn More.

For community providers wishing to refer their patients for monoclonal antibody treatment for COVID-19, visit this page.

COVID-19 Treatment Info

Monoclonal Antibody Treatment for COVID-19

With the emergence of the Omicron variant, which is now the dominant variant in United States, has come resistance to commercially available monoclonal antibody for COVID-19, excluding Sotrovimab. The federal government allocates this medication and we are working to secure monoclonal antibody treatment, however, we currently do not have supply of this pharmaceutical at this time. If and when monoclonal antibody treatment becomes available at Northern Arizona Healthcare, this page will be updated with the necessary information for community providers to refer their patients for monoclonal antibody treatment. If you have questions on whether or not you may qualify for this treatment, contact your primary care provider.

Click the button below for more information from the Arizona Department of Health Services on COVID-19 antivirals.

COVID-19 mAB TREATMENT

 

What is it?

Monoclonal antibody is a COVID treatment, given by infusion or injection, that works like your immune system to fight off infection by blocking the ability of COVID to enter human cells. The goal of this treatment is to prevent people at high risk of severe COVID from becoming sick enough that they need to be hospitalized.

This medication is investigational, and is not currently FDA approved, however, it is authorized for emergency use by the FDA.  This means that based on preliminary data, it is considered a reasonable treatment option for high risk patients with COVID in the first 10 days of their illness with the understanding that studies are ongoing into how well the medication works and how well it is tolerated. There are no other FDA authorized treatments for COVID-19 in the outpatient setting except for monoclonal antibody treatment. 

Am I eligible for monoclonal antibody infusion?

To receive this medication, a person meet the following criteria:

  • Be 18 years of age or older, AND
  • In the outpatient setting, AND
  • Have onset of symptoms must be less than 10 days prior to treatment, AND
  • Have positive COVID viral diagnostic test (not an antibody test), AND
  • Meet high risk criteria which includes:
    • Age >/=65, OR
    • Obesity, OR
    • Chronic kidney or liver disease, OR
    • Diabetes, OR
    • Weakened Immune system, OR
    • Heart disease (including high blood pressure, congestive heart failure, and congenital heart disease), OR 

    • Lung disease (e.g., COPD, moderate-severe asthma, interstitial lung disease, pulmonary Hypertension, cystic fibrosis, etc.), OR 

    • Neurologic or neurodevelopmental disorder (e.g., Stroke, cerebral palsy, downs syndrome) 

    • Sickle cell disease, OR 

    • Need for a medical device such as tracheostomy or  gastrostomy, OR 

    • Other medical conditions that may increase risk for progression to severe COVID-19 (e.g., race/ethnicity, substance abuse, pregnancy, complex medical condition) 

Talk with your health care provider about treatments that are right for you, including if you have other medical conditions not listed above.   

What are the side effects?

The most common reported side effects with monoclonal antibody therapies for COVID-19 are nausea, diarrhea, dizziness, headache, itchiness, and vomiting. The side effects of getting any medicine by vein may include brief pain, bleeding, bruising of the skin, soreness, swelling, and possible infection at the infusion site or injection site.

In clinical trials of monoclonal antibodies involving nearly 3,000 people, severe hypersensitivity reactions, including anaphylaxis, were reported. These reactions were very rare and all reactions were treated successfully and resolved. As clinical studies are ongoing, it is possible that all risks are not yet known. 

Because these treatments are antibody treatments, they may affect the body’s immune response to future COVID-19 infections or COVID-19 vaccine. COVID-19 vaccine must be delayed 90 days from monoclonal antibody infusion.

Can I still get monoclonal antibody therapy if I have received COVID-19 Vaccine?

If you have received one or two shots of COVID-19 vaccine, you are still eligible for treatment. For patients that have only received one shot of an mRNA vaccine, the second shot should be delayed by 90 days from monoclonal antibody infusion. The vaccine series does not need to be restarted. 

How can I get treatment?

Please call your primary care physician to be assessed for referral as soon as possible if you think you qualify as this treatment must be given within 10 days of symptom onset.

What is the cost? Will insurance cover the treatment?

Monoclonal antibody medication is provided by the federal government at no charge to patients, at this time. Insurance will be billed for any associated provider visit and the medication administration. Northern Arizona Healthcare will accept all patients in need of this therapy, regardless of insurance, and utilize financial assistance when needed.

Financial assistance information can be can be found at by visiting the Northern Arizona Healthcare Financial Assistance Program page or by emailing careassistance@NAHealth.com for the financial assistance application form.

Can I get a COVID-19 vaccine if I have had antibody treatment?

COVID-19 Vaccine must be delayed 90 days from monoclonal antibody infusion.

 

Antiviral Treatment for COVID-19

Northern Arizona Healthcare has requested allocation of the new antivirals for COVID-19 (Paxlovid and Molnupiravir), however, we currently do not have this medication available to our patients. COVID-19 antivirals are allocated by the state and may not be available to all patients. Your medical provider can determine whether you are a candidate for these medications.

Click the button below for more information from the Arizona Department of Health Services on COVID-19 antivirals.

COVID-19 ANTIVIRALS